# Immunologic and Clinical Sequelae after COVID-19 in Patients with Systemic Autoimmune Rheumatic Diseases

> **NIH NIH R01** · BRIGHAM AND WOMEN'S HOSPITAL · 2024 · $716,336

## Abstract

PROJECT SUMMARY
The 5 million Americans living with systemic autoimmune rheumatic diseases (SARDs), such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), are at increased risk of poor COVID-19 outcomes. SARO treatment with immunomodulators may lead to blunted and dysregulated immune responses to vaccination and infection. SARDs are characterized by a predisposition to autoantibody formation and fibrosis. These factors may place SARDs at risk for poor short-term outcomes (e.g., breakthrough infection, prolonged viral shedding) and post-acute sequelae of COVID-19 (PASC), characterized by prolonged COVID-19 symptoms (>/=28 days). PASC is of high clinical and

## Key facts

- **NIH application ID:** 10766202
- **Project number:** 5R01AR080659-02
- **Recipient organization:** BRIGHAM AND WOMEN'S HOSPITAL
- **Principal Investigator:** Jeffrey Andrew Sparks
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $716,336
- **Award type:** 5
- **Project period:** 2023-02-01 → 2028-01-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10766202

## Citation

> US National Institutes of Health, RePORTER application 10766202, Immunologic and Clinical Sequelae after COVID-19 in Patients with Systemic Autoimmune Rheumatic Diseases (5R01AR080659-02). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10766202. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*